Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

Kathleen N. Moore, Bradley J. Monk, John K. Chan et al.|The Lancet Oncology|2019

Cited by 533